心力衰竭患者的冠状动脉微血管功能障碍
Coronary microvascular dysfunction in heart failure patients.
作者信息
Toya Takumi, Nagatomo Yuji, Ikegami Yukinori, Masaki Nobuyuki, Adachi Takeshi
机构信息
Division of Cardiology, National Defense Medical College, Tokorozawa, Saitama, Japan.
出版信息
Front Cardiovasc Med. 2023 Jun 2;10:1153994. doi: 10.3389/fcvm.2023.1153994. eCollection 2023.
Abstract
Coronary microcirculation has multiple layers of autoregulatory function to maintain resting flow and augment hyperemic flow in response to myocardial demands. Functional or structural alterations in the coronary microvascular function are frequently observed in patients with heart failure with preserved or reduced ejection fraction, which may lead to myocardial ischemic injury and resultant worsening of clinical outcomes. In this review, we describe our current understanding of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved and reduced ejection fraction.
摘要
冠状动脉微循环具有多层自动调节功能，以维持静息血流，并根据心肌需求增加充血血流。在射血分数保留或降低的心力衰竭患者中，经常观察到冠状动脉微血管功能的功能或结构改变，这可能导致心肌缺血性损伤，并导致临床结局恶化。在这篇综述中，我们描述了目前对射血分数保留和降低的心力衰竭发病机制中冠状动脉微血管功能障碍的理解。
相似文献
1
Coronary microvascular dysfunction in heart failure patients.
Front Cardiovasc Med. 2023 Jun 2;10:1153994. doi: 10.3389/fcvm.2023.1153994. eCollection 2023.
2
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71. doi: 10.1016/j.jacc.2013.02.092. Epub 2013 May 15.
3
Correlation between longitudinal strain analysis and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.
Microcirculation. 2020 Apr;27(3):e12605. doi: 10.1111/micc.12605. Epub 2020 Jan 14.
4
Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.
Am J Physiol Heart Circ Physiol. 2018 May 1;314(5):H1033-H1042. doi: 10.1152/ajpheart.00680.2017. Epub 2018 Feb 9.
5
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction.
JAMA Cardiol. 2021 Oct 1;6(10):1130-1143. doi: 10.1001/jamacardio.2021.1825.
6
Microcirculation and Heart Failure.
Curr Pharm Des. 2018;24(25):2954-2959. doi: 10.2174/1381612824666180625143232.
7
Coronary Microcirculation in Heart Failure with Preserved Systolic Function.
Curr Pharm Des. 2018;24(25):2960-2966. doi: 10.2174/1381612824666180711124131.
8
Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.
Eur Heart J. 2021 Nov 14;42(43):4431-4441. doi: 10.1093/eurheartj/ehab653.
9
Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction.
Rev Cardiovasc Med. 2021 Mar 30;22(1):97-104. doi: 10.31083/j.rcm.2021.01.277.
10
Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction.
Eur J Heart Fail. 2020 Mar;22(3):432-441. doi: 10.1002/ejhf.1671. Epub 2019 Dec 15.
引用本文的文献
1
Inflammation mediated glycolipid dysregulation in coronary microvascular disease pathogenesis.
Sci Rep. 2025 Jul 2;15(1):22694. doi: 10.1038/s41598-025-08057-4.
2
Vascular (dys)function in the failing heart.
Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01163-w.
3
Microcirculatory dysfunction in patients with acute anterior myocardial infarction combined with new complete right bundle branch block.
BMC Cardiovasc Disord. 2025 May 29;25(1):414. doi: 10.1186/s12872-025-04872-9.
4
Heart failure and microvascular dysfunction: an in-depth review of mechanisms, diagnostic strategies, and innovative therapies.
Ann Med Surg (Lond). 2024 Dec 24;87(2):616-626. doi: 10.1097/MS9.0000000000002971. eCollection 2025 Feb.
5
Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.
World J Cardiol. 2025 Feb 26;17(2):103950. doi: 10.4330/wjc.v17.i2.103950.
6
Coronary Microvascular Dysfunction and Hypertension: A Bond More Important than We Think.
Medicina (Kaunas). 2023 Dec 11;59(12):2149. doi: 10.3390/medicina59122149.
7
The prevalence of coronary microvascular dysfunction (CMD) in heart failure with preserved ejection fraction (HFpEF): a systematic review and meta-analysis.
Heart Fail Rev. 2024 Mar;29(2):405-416. doi: 10.1007/s10741-023-10362-x. Epub 2023 Oct 23.
本文引用的文献
1
Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease.
Arterioscler Thromb Vasc Biol. 2023 May;43(5):774-783. doi: 10.1161/ATVBAHA.122.318928. Epub 2023 Mar 23.
2
Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction.
Circ Heart Fail. 2023 Apr;16(4):e010051. doi: 10.1161/CIRCHEARTFAILURE.122.010051. Epub 2023 Mar 10.
3
Effect of Training on Vascular Function and Repair in Heart Failure With Preserved Ejection Fraction.
JACC Heart Fail. 2023 Apr;11(4):454-464. doi: 10.1016/j.jchf.2022.12.011. Epub 2023 Mar 1.
4
Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines-Heart Failure Registry.
Eur J Heart Fail. 2023 Jan;25(1):63-73. doi: 10.1002/ejhf.2729. Epub 2022 Nov 20.
5
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
Cardiovasc Diabetol. 2022 Sep 3;21(1):173. doi: 10.1186/s12933-022-01607-4.
6
Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
N Engl J Med. 2022 Oct 13;387(15):1351-1360. doi: 10.1056/NEJMoa2206606. Epub 2022 Aug 27.
7
Coronary microvascular dysfunction is an independent predictor of developing cancer in patients with non-obstructive coronary artery disease.
Eur J Prev Cardiol. 2023 Feb 14;30(3):209-216. doi: 10.1093/eurjpc/zwac184.
8
Prognostic Impact of Coronary Flow Reserve in Patients With Reduced Left Ventricular Ejection Fraction.
J Am Heart Assoc. 2022 Aug 2;11(15):e025841. doi: 10.1161/JAHA.122.025841. Epub 2022 Jul 25.
9
Prognostic value of structural and functional coronary microvascular dysfunction in patients with non-obstructive coronary artery disease; from the multicentre international ILIAS registry.
EuroIntervention. 2022 Oct 21;18(9):719-728. doi: 10.4244/EIJ-D-22-00043.
10
Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction: A Modifiable Therapeutic Target?
JACC Cardiovasc Imaging. 2022 Jun;15(6):1012-1014. doi: 10.1016/j.jcmg.2022.04.008.
Zotero 插件